The effect of calcineurin inhibitors on endothelial function in renal transplant recipients

被引:51
|
作者
Oflaz, H
Turkmen, A
Kazancioglu, R
Kayacan, SM
Bunyak, B
Genchallac, H
Erol, B
Mercanoglu, F
Umman, S
Sever, MS
机构
[1] Istanbul Sch Med, Dept Cardiol, Istanbul, Turkey
[2] Istanbul Sch Med, Dept Radiodiagnost, Istanbul, Turkey
[3] Istanbul Sch Med, Dept Urol, Istanbul, Turkey
[4] Istanbul Sch Med, Dept Internal Med, Div Nephrol, Istanbul, Turkey
关键词
cyclosporine; endothelial function; renal transplantation; tacrolimus;
D O I
10.1034/j.1399-0012.2003.00030.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Endothelial dysfunction is of vital importance, as it may cause ischemia and dysfunction in various organs. Despite, this problem has been well documented in patients with end-stage renal disease (ESRD), there is not enough data considering this issue following renal transplantation. One of the potential causes of endothelial dysfunction in renal transplant recipients may be administration of calcineurin inhibitors. The aim of this study is to evaluate the effects of two different calcineurin inhibitors [cyclosporin A (CsA) and tacrolimus (FK506)] on endothelial function in renal transplant patients. Forty-four renal transplant recipients [22 on FK506 (group I) and 22 on CsA (group II)] were studied. Endothelial functions of the brachial artery were evaluated by using high resolution vascular ultrasound. Endothelium-dependent and -independent vasodilations were assessed by establishing reactive hyperemia and using sublingual nitroglycerine (NTG), respectively. Results are presented as percentage change from baseline values. Significant endothelial dysfunction was noted in renal transplant patients treated with CsA. While endothelium-dependent vasodilation was 12.1+/-5.1% in group I and it was 6.5+/-3.7% in group II (p<0.001). The increase in brachial artery diameter after sublingual NTG was 20.1+/-6.3 and 12.7+/-5.6% in groups I and II, respectively. This indicates that the endothelium-dependent and -independent vasodilation of the patients on FK506 is better preserved than the patients on CsA therapy. Besides, blood flow volume (BFV) increase was 51.2+/-39.4 and 43.9+/-24.3%, in groups I and II, respectively, in reactive hyperemia period (p>0.05). Post-transplant course of renal transplant recipients is complicated by endothelial dysfunction. This problem is more prominent in patients on CsA therapy, which can predispose these patients to more frequent cardiac complications.
引用
收藏
页码:212 / 216
页数:5
相关论文
共 50 条
  • [41] Interaction study between sildenafil and calcineurin inhibitors in renal transplant recipients with erectile dysfunction
    Cofán, F
    Gutiérrez, R
    Beardo, P
    Campistol, JM
    Oppenheimer, F
    Alcover, J
    [J]. NEFROLOGIA, 2002, 22 (05): : 470 - 476
  • [42] A Retrospective Comparison of Medication Regimen Complexity in Renal Transplant Recipients Receiving Calcineurin Inhibitors
    Zuberi, Muhammad
    Hamandi, Bassem
    Harrison, Jennifer
    Ingram, Sara
    [J]. CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2006, 59 : 39 - 39
  • [43] Steroid withdrawal in renal transplant recipients treated with m-TOR inhibitors without calcineurin inhibitors
    Franco, Antonio
    Cotilla, Eva
    Roca, Susana
    Jimenez, Luis
    Sanchez, Jose
    Olivares, Jesus
    [J]. TRANSPLANT INTERNATIONAL, 2007, 20 : 128 - 128
  • [44] Atorvastatin improves endothelial function in renal-transplant recipients
    Åsberg, A
    Hartmann, A
    Fjeldså, E
    Holdaas, H
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (09) : 1920 - 1924
  • [45] Black tea improves endothelial function in renal transplant recipients
    Ardalan, M. R.
    Tarzamni, M. K.
    Shoja, M. M.
    Tubbs, R. S.
    Rahimi-Ardabili, B.
    Ghabili, K.
    Khosroshahi, H. T.
    [J]. TRANSPLANTATION PROCEEDINGS, 2007, 39 (04) : 1139 - 1142
  • [46] Sirolimus as Primary Immunosupression Is Associated with Improved Renal Function and Survival Compared with Calcineurin Inhibitors in Stable Cardiac Transplant Recipients
    Al-Omari, M. A.
    Raichlin, E.
    Pereira, N. L.
    Edwards, B. S.
    Clavell, A. L.
    Rodeheffer, R. J.
    Frantz, R. P.
    Schirger, J. A.
    Kushwaha, S. S.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2010, 29 (02): : S23 - S23
  • [47] Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors
    de Denus, Simon
    Zakrzewski, Marcin
    Barhdadi, Amina
    Leblanc, Marie-Helene
    Racine, Normand
    Belanger, Francois
    Carrier, Michel
    Ducharme, Anique
    Dube, Marie-Pierre
    Turgeon, Jacques
    White, Michel
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (03): : 326 - 331
  • [48] Belatacept in kidney transplant recipients switched from calcineurin inhibitors: results on renal function and safety after 6 months
    Bardo, P.
    Berdougo, B.
    Rouimi, E.
    Grimbert, P.
    Astier, A.
    Paul, M.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (06) : 1301 - 1302
  • [49] SIROLIMUS AS PRIMARY IMMUNOSUPPRESSION IS ASSOCIATED WITH IMPROVED RENAL FUNCTION AND SURVIVAL COMPARED WITH CALCINEURIN INHIBITORS IN STABLE CARDIAC TRANSPLANT RECIPIENTS
    Al-Omari, M. A.
    Raichlin, E.
    Edwards, B. S.
    Rodeheffer, R. J.
    Frantz, R. P.
    Pereira, N. L.
    Clavell, A. L.
    Kushwaha, S. S.
    [J]. HEART, 2010, 96 : A38 - A38
  • [50] Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus
    Backman, L
    Reisæter, AV
    Wramner, L
    Ericzon, BG
    Salmela, K
    Brattström, C
    [J]. CLINICAL TRANSPLANTATION, 2006, 20 (03) : 336 - 339